<DOC>
	<DOCNO>NCT01484574</DOCNO>
	<brief_summary>This open label , non-randomized , dose range study evaluate safety efficacy different dos Stempeucel critical limb ischemia patient .</brief_summary>
	<brief_title>A Clinical Trial Study Efficacy Safety Different Doses Bone Marrow Derived Mesenchymal Stem Cells Patients With Critical Limb Ischemia Due Buergers Disease</brief_title>
	<detailed_description />
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Thromboangiitis Obliterans</mesh_term>
	<criteria>Buerger 's disease diagnose Shionoya criterion Males female ( willing use accept method contraception course study ) age group 1865 yr Established CLI study limb , clinically hemodynamically confirm per Rutherford III5 Patients Rutherford III6 gangrene extend maximally head metatarsal limit toe ( Patients wet gangrene must undergo wound debridement / amputation screen ) Patients infrapopliteal occlusive disease rest pain ischemic ulcer/necrosis , eligible fail traditional revascularization treatment per investigator judgment ( No option patient ) Ankle Brachial Pressure Index ( ABPI ) ≤ 0.6 ankle pressure ≤ 50 mm Hg TcPO2 ≤ 40 mmHg foot study limb Patients able understand requirement study , willing provide voluntary write informed consent video consent , abide study requirement , agree return require followup visit Patients CLI indicate major amputation screen Atherosclerotic PAD Ulcers exposure tendon and/bone shin region Previous transmetatarsal amputation study limb Any Lumbar sympathectomy procedure perform less 90 day prior screen Patients gait disturbance reason CLI Diagnosis diabetes mellitus ( type 1 type 2 ) Patients leave ventricular ejection fraction &lt; 35 % Patients suffer clinically relevant peripheral neuropathy History Stroke myocardial infarction Patients contraindicate MRA Patients deep vein thrombosis limb Patients clinically serious and/or unstable intercurrent infection , medical illness condition uncontrolled whose control , opinion Investigator , may jeopardize participation study complication therapy Documented terminal illness cancer concomitant disease process life expectancy &lt; 1 year Patients already enrol another investigational drug trial complete within 3 month participate stem cell clinical trial Patient know hypersensitivity constituent IMP dimethyl sulfoxide ( DMSO ) human serum albumin ( HSA ) History severe alcohol drug abuse within 3 month screen Hb % &lt; 10 gm % male , Hb % &lt; 9 gm % female , serum creatinine ≥ 2mg % , serum Total Bilirubin ≥2mg % Pregnant lactating woman Patients test positive HIV 1 , HCV , HBV , CMV , RPR</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Critical limb ischemia</keyword>
	<keyword>Buerger 's disease</keyword>
	<keyword>Critical limb ischemia due Buerger 's disease</keyword>
</DOC>